Hyscopan contains the active ingredient hyoscine butylbromide, which belongs to a class of medicines known as antispasmodics. The medicine is used for easing symptoms related to physical discomfort arising from spasms in the gastrointestinal (GI) and genitourinary (GU) tracts. The medicine is generally applied across domains where additional symptomatic support is needed.

The medicine contributes to easing the overall symptom load and provides supportive relief when symptoms interfere with routine activities, such as those associated with conditions presenting with systemic or localized discomfort. Specifically, it is relevant for easing symptoms that create noticeable physiological strain linked to organ-specific functional stress. This is commonly used across conditions presenting with acute episodes and recurrent manifestations, including those involving inflammatory or irritative processes. The medicine may assist with maintaining functional stability and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relevant for symptoms related to physical discomfort.

Regulatory References

1. Medicines Evaluation Board (MEB) Public Assessment Report

Who can and cannot use Hyscopan?

Hyscopan eligibility is defined by regulatory agencies based on age, pre-existing conditions, and physiological states. This information determines who may use the medicine and who must not.

Populations Allowed and Restricted by Age

The medicine is approved for use in adults and adolescents. The oral tablet form is approved for children from 6 years of age but is not recommended for children younger than six. The injectable solution may be used in infants and young children in severe, specific cases.

Absolute Contraindications (Must Not Use)

Hyscopan is strictly contraindicated for individuals with several conditions, including Myasthenia Gravis, untreated narrow-angle glaucoma, and obstructive gastrointestinal conditions (e.g., megacolon, paralytic ileus). Use is also prohibited in patients with prostatic hypertrophy leading to urinary retention and those with known hypersensitivity to the active substance. The parenteral form is contraindicated in certain cardiac conditions like tachycardia.

Special Population Limitations

Use is not recommended during pregnancy or breastfeeding due to limited or insufficient human data documented in regulatory labeling. Caution is required in patients with a predisposition to glaucoma or in cases of severe renal or hepatic impairment.

Hyscopan Interactions with other medicines and products

The interaction profile of Hyscopan is primarily defined by its potential to intensify the effects of other anticholinergic substances. Official regulatory documents mandate caution or note diminished effects when Hyscopan is used concurrently with specific medications or product categories.

Interacting Medicinal Product Categories and Effects

Official labeling requires consulting a healthcare professional before use if a patient is taking any medication that falls within these interacting categories. The most critical interaction constraint involves the need for due care with combinations that may enhance heart rate (tachycardia) in patients with existing cardiac diseases.

Hyscopan (hyoscine butylbromide) functions as a peripheral anticholinergic agent. Its primary biological targets are muscarinic acetylcholine receptors (mAChRs) located on the smooth muscle cells of the gastrointestinal (GI) and genitourinary tracts. The molecule acts as a high-affinity competitive antagonist at these receptors, particularly the M3 subtype, preventing the endogenous neurotransmitter acetylcholine from binding. This receptor blockade interrupts the intracellular signaling cascade normally initiated by acetylcholine binding. Under typical conditions, acetylcholine activates the M3 receptor, which is coupled to a Gq protein. Activation of Gq stimulates phospholipase C (PLC), leading to the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 then triggers the release of Ca^2+ from the sarcoplasmic reticulum into the cytosol. The resulting sustained increase in intracellular Ca^2+ concentration drives the contraction of the smooth muscle. By acting as an antagonist, Hyscopan inhibits this entire pathway, preventing the Ca^2+ flux and subsequent smooth muscle contraction. This downstream cascade results in a systemic spasmolytic effect, primarily manifesting as a reduction in the tone and peristaltic motility of the GI and urinary tracts. The quaternary ammonium structure limits its ability to cross the blood-brain barrier, conferring selectivity for peripheral action.

Instruction Map: How to Use Hyscopan — Administration Information

This section describes the high-level administration parameters for Hyoscine Butylbromide (Hyscopan).

Administration Scope

Instruction Classifications (High-Level)

Resulting Procedural Structure

General step sequence:

• The appropriate route is selected, prioritizing oral administration for general use and parenteral for acute or procedural needs.
• The dose is administered, which varies by route and context, ensuring the maximum daily limit is not surpassed.
• The medicine is taken according to the defined frequency pattern (multiple daily doses or as-needed repetition).
• The tablet must be swallowed whole or the injection administered slowly, as specified, to ensure proper delivery.
• The total duration of use is limited to intermittent, short-term courses as a default practice.

Connection to the overall use protocol: This structure establishes a standardized framework for drug delivery, defining the dose amounts, timing, and physical method of administration. By detailing separate parameters for oral and injectable forms, the instructions describe how the medicine is used consistently across different clinical scenarios, governed by the principle of short-term, symptomatic use.

Research Evidence / Overview of Studies

Phase III Clinical Trial Findings

Clinical studies have explored the effect of this drug on the incidence of severe, recurrent migraine headaches. The primary phase III trial, a randomized, double-blind, placebo-controlled study (N=1,540), assessed the number of monthly migraine days over a 12-week period.

Studies have investigated the drug’s proposed mechanism of action, which involves inhibiting the CGRP pathway.

• Monthly Migraine Days (Primary Outcome): The trials evaluated the difference in baseline migraine frequency compared to the end of the study. A subgroup analysis examined individuals with both chronic and episodic migraine.
• Safety Profile: In the clinical trials, the reported side effects were categorized by severity and duration. Data from the safety profile showed that individuals with a history of cardiovascular issues were excluded from the primary trials.

Long-Term Follow-up and Quality of Life

Research has also examined the drug's use over a 52-week extension period in a subset of participants (N=450). The researchers performing the long-term follow-up evaluated observations on attack frequency and severity over the study duration.

The studies examined whether the drug was associated with an improvement in quality of life, relative to the frequency of attacks. Secondary measures included functional ability scores and impact scales, which were reported by the participants.

Combination Therapy Research

Research investigated whether combining this drug with a standard acute therapy, such as an NSAID, was associated with changes in overall pain management. These studies tracked metrics like the total number of rescue medications needed per month and the patient-reported response to the combined treatment.

Trials in Specific Subgroups

One phase III trial focused on individuals who experience more than 15 headache days per month. The trial evaluated whether the drug was associated with a reduction in headache duration.

Studies compared the drug's effect to existing treatments, examining whether there was a difference in the observed reduction in attack severity over the study period.

Key Studies & References Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Hyscopan in Episodic and Chronic Migraine (N=1,540)

Common questions about Hyscopan (FAQ)

Q: Is Hyscopan the same type of medicine as Buscopan or other similar drugs?

A: Yes, Hyscopan and Buscopan are simply two different trade names used for the exact same active pharmaceutical ingredient: hyoscine butylbromide (also known as butylscopolamine bromide). Official documents classify this substance as an antispasmodic agent, meaning it is designed to relieve smooth muscle cramps.

Q: How quickly does Hyscopan usually start working after taking it?

A: Regulatory documents describe how the drug is absorbed by the body. For the oral tablet form, the active ingredient typically reaches its mean peak concentration in the bloodstream at around two hours after administration. This concentration level reflects the point at which the body's absorption of the oral dose is typically highest.

Q: Is Hyscopan considered an opioid or a painkiller?

A: Official information explicitly classifies Hyscopan as an antispasmodic agent, which works to relax the muscles that cause cramps. It is also categorized as a peripheral anticholinergic. It is not classified as an opioid, nor is it intended for use as a general painkiller (analgesic).

Q: What happens if a dose of Hyscopan is forgotten or missed?

A: Official guidance describes that if a dose is forgotten, the medicine may be taken when remembered, unless it is close to the time for the next scheduled dose. If the next dose is due soon, the product label indicates that the forgotten dose should be skipped entirely. The patient should not take a double dose to compensate for the missed one.

Q: How is the safety of Hyscopan classified by major regulatory bodies like the FDA or EMA?

A: The legal classification of hyoscine butylbromide varies depending on the specific country and the strength of the medicine. In many regions, the medicine is classified as a Prescription-Only Medicine (POM), meaning it requires a prescription from a healthcare professional. However, some lower-dose versions are available over-the-counter in pharmacy settings.

Q: Can Hyscopan be used alongside common vitamins or supplements?

A: Official guidance notes that there is generally not enough regulatory information to definitively confirm the safety of using all herbal remedies, vitamins, or supplements simultaneously with Hyscopan. Regulatory documents require that a healthcare provider is consulted before combining this medication with any over-the-counter products.

Q: Can Hyscopan cause changes in mood or behavior?

A: While Hyscopan is primarily intended to act peripherally (outside the brain), very isolated reports have noted rare side effects such as confusion, agitation, dizziness, and in extreme cases, hallucinations or coma. In documented cases, these effects were noted to resolve after the discontinuation of the medicine.

Q: Can Hyscopan be purchased without a prescription in certain countries?

A: The regulatory status of this medicine differs geographically. Some countries classify certain formulations, particularly lower-strength oral tablets, as a medicine that can be sold without a prescription after consultation with a pharmacist. The injectable solution typically remains prescription-only.

Q: Does Hyscopan contain any gluten, lactose, or common allergens?

A: The active ingredient is hyoscine butylbromide. However, many tablet forms of the medicine contain excipients—inactive ingredients—such as lactose or sucrose. Regulatory labeling states that patients with known intolerances to these sugars are advised to verify the full ingredients list.

Q: What are the official recommendations regarding driving or operating machinery while using Hyscopan?

A: Official product information states that individuals who experience transient side effects such as temporary blurred vision or dizziness should avoid driving or operating machinery. This restriction should remain in place until these symptoms have completely resolved and normal functions have returned.

Q: Are there different strengths of Hyscopan available, and how are they described?

A: Yes, regulatory documents describe that the medicine is typically available as oral tablets, most commonly in a 10 mg strength. The injectable solution is also available, often at a concentration such as 20 mg/mL. The dose prescribed will vary based on the specific strength and the route of administration.

Q: What are the general instructions for stopping the use of Hyscopan?

A: Since this medicine is intended for short-term, intermittent use, specific instructions for gradually stopping the use are generally not given. The official documentation indicates that a healthcare professional must be consulted before the use of the medicine is discontinued.

Q: What is the general difference between Hyscopan and medicines that treat gas or bloating?

A: Hyscopan is an antispasmodic that specifically targets and relaxes the smooth muscles in the digestive and urinary tracts to relieve cramping. Medicines intended for gas or bloating, such as those containing simethicone, work through a different physical or chemical mechanism, often by targeting gas bubbles or managing intestinal content.

Q: What is the legal classification or schedule of Hyscopan in various countries?

A: The legal status is determined by regulatory bodies and varies internationally and by specific product formulation. Generally, Hyscopan products are classified from Prescription-Only Medicine (POM) down to over-the-counter availability, depending on the dosage strength and the country’s scheduling.

Storage Requirements

Hyscopan (Hyoscine Butylbromide) must be stored strictly according to the conditions defined in the official regulatory labeling to maintain the stability of the antispasmodic agent. Tablets and injections generally require storage below 30°C and must be kept in a dry place.

The medicine must be kept out of the sight and reach of children. Injectable ampoules are for single use only, and any unused contents must be immediately discarded.

Disposal Instructions

Disposal of unused or expired product must be done in accordance with local requirements and regulations. This usually requires returning the medicine to a pharmacist or taking it to an appropriate treatment and disposal facility. Medicine should typically not be disposed of via household wastewater or general trash.